Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Cleveland-Cliffs Inc. Announces Proposed Offering of $600 Million of Senior Unsecured Guaranteed Notes

(NYSE:CLF) CLEVELAND--(BUSINESS WIRE)--Cleveland-Cliffs Inc. (NYSE: CLF) (“Cliffs”) announced today that it intends to offer to sell, subject to market and other conditions, $600 million aggregate ...

How will the proceeds from the offering be allocated—e.g., for debt refinancing, capital expenditures, or working capital—and what impact will that have on CLF's cash flow and operations? What is the expected yield and pricing of the 2034 senior unsecured guaranteed notes relative to current market rates? How will the $600 million note issuance affect CLF's leverage ratio and credit rating?
Symbol: CLF
Debt offering
11 days ago
Read more businesswire

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

(NASDAQ:TGTX) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase progr...

Is the timing of the repurchase aligned with expected earnings releases or catalyst events that could amplify the stock’s momentum? What does the initiation of a new $100 million repurchase program signal about management’s confidence and how does it compare to peer buyback activity in the biotech sector? How will the completed $100 million buyback affect TG Therapeutics’ short‑term liquidity and valuation metrics?
Symbol: TGTX
Buybacks
11 days ago
Read more globenewswire

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

(NASDAQ:ENGN) BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced it has achieved i...

What are the potential market size and revenue upside if the Phase 2 data support a successful launch, and how might that affect long‑term growth forecasts for enGene? What does the enrollment rate and trial design suggest about the timeline for data read‑outs and potential regulatory filing compared to other NMIBC gene‑therapy competitors? How will achieving the 100‑patient enrollment milestone in the LEGIT pivotal cohort influence enGene’s short‑term stock momentum and valuation multiples?
Symbol: ENGN
Clinical trials
11 days ago
Read more businesswire

Exro Provides Corporate Update, Postpones Annual General Meeting

(EXRO) CALGARY, AB, Sept. 3, 2025 /PRNewswire/ - Exro Technologies Inc. (TSX: EXRO) ("Exro" or the "Company") provides the following corporate update. Exro's strategic review process is ongoing, wi...

How does postponing the Annual General Meeting impact shareholder rights and voting power, and could it signal governance concerns? What is the expected timeline and likelihood of completing the strategic review and any resulting transaction? How will the potential sale of Exro's intellectual property affect its valuation and share price in the short term?
Symbol: EXRO
Mergers
11 days ago
Read more prnewswire

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

(NASDAQ:CGTX) PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neur...

How does CT1812's mechanism and trial design compare with other late‑stage Alzheimer’s candidates, and what could that mean for market positioning if the study succeeds? What are the primary risks that could delay full enrollment or compromise the integrity of the START study results? How will the 75% enrollment milestone affect CGTX's near‑term share price and trading volume?
Symbol: CGTX
Clinical trials
11 days ago
Read more globenewswire